A5049599426- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- Diet, Metabolism, and Disease
- Hepatitis Viruses Studies and Epidemiology
- Influenza Virus Research Studies
- Virology and Viral Diseases
- Tuberculosis Research and Epidemiology
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Rabies epidemiology and control
- Animal Virus Infections Studies
- Advanced biosensing and bioanalysis techniques
- Respiratory viral infections research
- Syphilis Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Viral gastroenteritis research and epidemiology
- Diagnosis and treatment of tuberculosis
- Poxvirus research and outbreaks
- Escherichia coli research studies
- Travel-related health issues
Siriraj Hospital
2015-2024
Mahidol University
2015-2024
University of Nebraska Medical Center
1999
Raltegravir is an HIV-1 integrase strand-transfer inhibitor with potent in vitro activity. This study explored the antiretroviral activity and safety of raltegravir treatment-naive patients plasma RNA levels > or = 5000 copies/mL CD4 T-cell counts 100 cells/mm.Multicenter, double-blind, randomized, controlled at doses 100, 200, 400, 600 mg twice daily versus efavirenz a dose mg/d, all combination tenofovir 300 mg/d lamivudine (clinicaltrials.gov identifier: NCT00100048).In 198 treated (160...
The purpose of this study was to evaluate the safety and efficacy raltegravir vs efavirenz-based antiretroviral therapy after 96 weeks in treatment-naive patients with HIV-1 infection.Multicenter, double-blind, randomized (100, 200, 400, or 600 mg twice a day) efavirenz (600 every day), both tenofovir/lamivudine (TDF/3TC), for 48 weeks, which arms were combined all dosed at 400 day. Eligible had RNA > =5000 copies per milliliter CD4 T cells =100 microliter.One hundred ninety-eight treated;...
New evidence has emerged regarding when to commence antiretroviral therapy (ART), optimal treatment regimens, management of HIV co-infection with opportunistic infections, and ART failure. The 2014 guidelines were developed by the collaborations Department Disease Control, Ministry Public Health (MOPH) Thai AIDS Society (TAS). One major changes in included recommending initiating irrespective CD4 cell count. However, it is an emphasis that commencing HAART at count above 500 cell/mm(3) for...
Although antiretroviral therapy (ART) has been rapidly scaled up in Asia, most HIV-positive patients the region still present with late-stage HIV disease. We aimed to determine trends of pre-ART CD4 levels over time Asian and factors associated late ART initiation.Data from two regional cohort observational databases were analyzed for median cell counts at initiation proportion (CD4 <200 cells/mm(3) or prior AIDS diagnosis). Predictors mortality determined.A total 2737 ART-naïve 22 sites 13...
Many HIV-infected individuals do not enter health care until late in the infection course. Despite encouraging earlier testing, this situation has continued for several years. We investigated prevalence of presenters and factors associated with presentation among patients an Asian regional cohort. This cohort study included their first positive HIV test during 2003-2012 CD4 count clinical status data within 3 months that test. Factors into (CD4 <200 cells/μl or AIDS-defining event ±3 test)...
We assessed the effects of hepatitis B (HBV) or C (HCV) co-infection on outcomes antiretroviral therapy (ART) in HIV-infected patients enrolled TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort Asia-Pacific region.Patients testing HBs antigen (Ag) HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV co-infected. Factors associated with and/or by logistic regression models. post-ART immunological response (CD4 change after six months) and virological...
The aim of this study was to identify baseline prognostic factors for poor clinical outcome HIV-associated cryptococcal meningitis. We conducted a trial in Thailand and the USA comparing low- high-dose concomitant use amphotericin B fluconazole meningitis followed by fluconazole. Subjects who were either alive cerebrospinal fluid (CSF) culture-positive or dead considered have outcome. At day 14, characteristics associated with included: low weight, high CSF antigen (CrAg) titre white blood...
We compared treatment outcomes of transmitted drug resistance (TDR) in patients on fully or partially sensitive regimens.Factors associated with survival and failure were analyzed using Cox proportional hazards discrete time conditional logistic models.TDR, found 60 (4.1%) 1471 Asian treatment-naive patients, was one the significant predictors failure. Patients TDR to >1 their regimen >3 times as likely fail no TDR.TDR context non-fully regimens. Efforts are needed incorporate testing into...
To evaluate safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F], followed by 23-valent polysaccharide (PPSV23) 8 weeks later, in adults living with HIV.In this phase 3 study (V114-018; NCT03480802), vaccine-naive HIV (CD4+ cell count ≥50 cells/μl, plasma RNA <50 000 copies/ml, receiving antiretroviral therapy) were randomized 1 : to receive one dose or licensed 13-valent PCV...
Objective The aim of the study was to determine risk factors for developing severe hepatotoxicity (grade 3 or 4 hepatotoxicity) and rash‐associated (rash with ≥grade 2 among women initiating nevirapine‐based antiretroviral therapy (ART). Methods Non‐Nucleoside Reverse Transcriptase Inhibitor Response Study a prospective cohort carried out in Zambia, Thailand Kenya. Between May 2005 January 2007, we enrolled antiretroviral‐naïve HIV‐infected ART. At enrolment at weeks 2, 4, 8, 16 24,...
Raltegravir 1200mg (2×600mg tablets) once daily (QD) demonstrated noninferior efficacy and similar safety to raltegravir 400mg twice (BID) at week 48 of the ONCEMRK trial. Here, we report 96 results from this study.ONCEMRK is a phase 3, multicenter, double-blind, noninferiority trial comparing QD with BID in treatment-naive HIV-1-infected adults. Participants were assigned (2:1) 2×600mg or BID, both emtricitabine tenofovir disoproxil fumarate (FTC/TDF) for weeks. Randomization was stratified...
Abstract Background Food frequency questionnaires (FFQ) are a useful dietary assessment tool to determine relationships between diet and non-communicable diseases (NCDs). Our purpose was validate semiquantitative FFQ (semi-FFQ) for Thais at risk of metabolic syndrome (MS). Methods The researchers identified 345 men women aged 30–65 years who were eligible the study. Ninety-four participants finally enrolled (54 in “urine-collection not-required” group 40 “urine collection” group). They asked...
We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism viral replication inhibition. This was randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included subjects receiving either compound, ABX464 (n = 6), or corresponding placebo 2), according randomization code. The first dose administered 25 mg, given once 3 times day over 2-...
Raltegravir as initial HIV therapy was examined in a double-blind study; 160 patients were randomized to raltegravir (400 mg bid after dose-ranging), 38 efavirenz, both with tenofovir/lamivudine. At week 240, HIV-RNA remained <50 copies per milliliter 68.8% (raltegravir) versus 63.2% (efavirenz), and CD4 increases 302 276 cells microliter, respectively. Early decline predicted later groups. resistance observed 3 of 10 recipients virologic failure. Few drug-related adverse events reported 48....
Background Antiretroviral therapy (ART) has evolved rapidly since its beginnings. This analysis describes trends in first-line ART use Asia and their impact on treatment outcomes. Methods Patients the TREAT HIV Observational Database receiving for ≥6 months were included. Predictors of failure modification assessed. Results Data from 4662 eligible patients was analysed. started 2003–2006 (n = 1419), 2007–2010 2690) 2011–2013 553). During observation period, tenofovir, zidovudine abacavir...
Background In resource-limited settings, routine monitoring of renal function during antiretroviral therapy (ART) has not been recommended. However, concerns for tenofovir disoproxil fumarate (TDF)-related nephrotoxicity persist with increased use. Methods We investigated serum creatinine (S-Cr) rates before and ART the incidence prevalence dysfunction after starting TDF by using data from a regional cohort HIV-infected individuals in Asia-Pacific. Time to was defined as time initiation...
Multiple comorbidities among HIV-positive individuals may increase the potential for polypharmacy causing drug-to-drug interactions and older with comorbidities, particularly those cognitive impairment, have difficulty in adhering to complex medications. However, effects of age-associated on treatment outcomes combination antiretroviral therapy (cART) are not well known. In this study, we investigated therapeutic cART adults Asian countries.
The emergence and transmission of HIV-1 drug resistance (HIVDR) has raised concerns after rapid global antiretroviral therapy (ART) scale-up. There are limited data on the epidemiology primary HIVDR in resource-limited settings Asia. We aimed to determine prevalence compare distribution a cohort ART-naïve Asian patients with recent chronic infection.Multicenter prospective study was conducted between 2007 2010. Resistance-associated mutations (RAMs) were assessed using World Health...